Effect of the inhibition of CYP3A4 or CYP2D6 on the pharmacokinetics and pharmacodynamics of oxycodone

被引：0
|
作者：
Oliver Kummer
Felix Hammann
Claudine Moser
Olivier Schaller
Jürgen Drewe
Stephan Krähenbühl
机构：
[1] University Hospital,Division of Clinical Pharmacology and Toxicology, Department of Biomedicine
[2] Mundipharma Medical Company,undefined
来源：
European Journal of Clinical Pharmacology | 2011年 / 67卷
关键词：
Oxycodone; Ketoconazole; Paroxetine; Drug interactions; Pharmacokinetics; Pharmacodynamics;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：63 / 71
页数：8
相关论文
共 50 条
  • [31] Dynamics and persistence of CYP2D6 inhibition by paroxetine
    Jurica, J.
    Zourkova, A.
    JOURNAL OF CLINICAL PHARMACY AND THERAPEUTICS, 2013, 38 (04) : 294 - 300
  • [32] Donepezil plasma concentrations, CYP2D6 and CYP3A4 phenotypes, and cognitive outcome in Alzheimer's disease
    Coin, A.
    Pamio, M. V.
    Alexopoulos, C.
    Granziera, S.
    Groppa, F.
    de Rosa, G.
    Girardi, A.
    Sergi, G.
    Manzato, E.
    Padrini, R.
    EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 2016, 72 (06) : 711 - 717
  • [33] Effect of CYP3A4 induction and inhibition on the pharmacokinetics of SHR0302 in healthy subjects
    Zhang, Zhe
    Gao, Xuehu
    Zhang, Ping
    Li, Yuan
    Fu, Meng
    Lin, Hongda
    Feng, Sheng
    Shen, Kai
    Yu, Guoning
    Li, Xin
    BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 2023, 89 (08) : 2561 - 2568
  • [34] Effects of CYP3A4 inducers with and without CYP3A4 inhibitors on the pharmacokinetics of maraviroc in healthy volunteers
    Abel, Samantha
    Jenkins, Timothy M.
    Whitlock, Lyndsey A.
    Ridgway, Caroline E.
    Muirhead, Gary J.
    BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 2008, 65 : 38 - 46
  • [35] Effects of efonidipine on the pharmacokinetics and pharmacodynamics of repaglinide: possible role of CYP3A4 and P-glycoprotein inhibition by efonidipine
    Li, Cheng
    Choi, Dong-Hyun
    Choi, Jun-Shik
    JOURNAL OF PHARMACOKINETICS AND PHARMACODYNAMICS, 2012, 39 (01) : 99 - 108
  • [36] Effects of efonidipine on the pharmacokinetics and pharmacodynamics of repaglinide: possible role of CYP3A4 and P-glycoprotein inhibition by efonidipine
    Cheng Li
    Dong-Hyun Choi
    Jun-Shik Choi
    Journal of Pharmacokinetics and Pharmacodynamics, 2012, 39 : 99 - 108
  • [37] Influence of CYP3A4 Induction/Inhibition on the Pharmacokinetics of Vilazodone in Healthy Subjects
    Boinpally, Ramesh
    Gad, Nayra
    Gupta, Samir
    Periclou, Antonia
    CLINICAL THERAPEUTICS, 2014, 36 (11) : 1638 - 1649
  • [38] Effect of CYP2D6 genetic polymorphism on the population pharmacokinetics of tipifarnib
    Juan Jose Perez-Ruixo
    Peter Zannikos
    Vural Ozdemir
    Monique A. Franc
    Stephan Francke
    Vladimir Piotrovsky
    Cancer Chemotherapy and Pharmacology, 2006, 58 : 681 - 691
  • [39] Allele and Genotype Frequencies of CYP3A4, CYP2C19, and CYP2D6 in Han, Uighur, Hui, and Mongolian Chinese Populations
    Zuo, Liang Jin
    Guo, Tao
    Xia, Dong Ya
    Jia, Li Hui
    GENETIC TESTING AND MOLECULAR BIOMARKERS, 2012, 16 (02) : 102 - 108
  • [40] Involvement of CYP3A4/5 and CYP2D6 in the metabolism of aconitine using human liver microsomes and recombinant CYP450 enzymes
    Tang, Lan
    Ye, Ling
    Lv, Chang
    Zheng, Zhijie
    Gong, Yun
    Liu, Zhongqiu
    TOXICOLOGY LETTERS, 2011, 202 (01) : 47 - 54
12345